A fully-owned private company

Leman Cardiovascular has raised over US$ 18 million (€ 15 million/CHF 22 million) from private investors to fund its activities to date. This round will secure product development, clinical trials, regulatory approval and market launch.

Leman Cardiovascular’s business model is to develop, manufacture and market innovative implantable devices in cardiovascular surgery using its extensive knowledge and proprietary technology in tissue processing and manufacturing. The development of a novel biological heart valve is the first step.

The company’s business strategy is two-fold:

• Growth through acquisition
• Partnership with companies specialised in cardiac devices to initiate the clinical phase in the United States

Leman Cardiovascular offers:

• Experienced management team with exhaustive experience of the cardiovascular surgical field and a successful track record of bringing products to market
• Innovative technology for the third generation of heart valves
• Strong pipeline of cardiovascular surgery products
• Certified manufacturing sites

Please contact us for further information: businessdevelopment@lemancardio.com